Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection

Expert Review of Molecular Diagnostics

Volumn 7, Issue 2, 2007, Pages 117-131

  Malinowski, Douglas P ^a  

^a BD Diagnostics Diagnostic Systems TriPath   (United States)

Author keywords

Biomarker; Cervical neoplasia; Clinical molecular diagnostics

Indexed keywords

BETA CATENIN; BETA3 INTEGRIN; BIOLOGICAL MARKER; CATHEPSIN F; CLAUDIN 1; CLAUDIN 7; CYCLIN E; GELATINASE B; KALININ; KI 67 ANTIGEN; PROTEIN P16INK4A; SCLEROPROTEIN; UVOMORULIN; VIRUS VACCINE; WNT PROTEIN;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME REARRANGEMENT; CLINICAL RESEARCH; DISEASE PREDISPOSITION; DNA REPLICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENOMICS; HUMAN; IMMUNOCYTOCHEMISTRY; INFECTION RISK; MICROARRAY ANALYSIS; PAPANICOLAOU TEST; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ANIMALS; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34047187922     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.2.117     Document Type: Review

References (115)

1. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19(6), 1865-1878 (2001).
2. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin. Chem. 48(8), 1151-1159 (2002).
3. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 38, S17-S23 (2005).
4. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87(2), 159-170 (1996).
5. Milyavsky M, Tabach Y, Shats I et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res. 65(11), 4530-4543 (2005). • Key paper that defined the contribution of discrete changes in key tumor suppressors and oncogenes to neoplasia development.
6. Ayllon V, Rebollo A. Ras-induced cellular events (review). Mol. Membr. Biol. 17(2), 65-73 (2000).
7. Fletcher JA. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin. Oncol. 31(2 Suppl. 6), 4-11 (2004).
8. Singh D, Febbo PG, Ross K et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1(2), 203-209 (2002).
9. Laird PW. Cancer epigenetics. Hum. Mol. Genet. 14(Spec. No. 1), R65-R76 (2005).
10. Ross JS, Fletcher JA, Bloom KJ et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 3(4), 379-398 (2004).
11. Rao PH, Arias-Pulido H, Lu XY et al. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 4(1), 5 (2004).
12. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001).
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000). •• Classic review article that describes the hallmarks of cancer.
14. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12, 186-192 (1993).
15. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 92, 727-735 (1998).
16. Cox JT, Schiffman M, Solomon D; ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am. J. Obstet. Gynecol. 188, 1406-1412 (2003).
17. Arbyn M, Buntinx F, Van Ranst M et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl Cancer Inst. 96, 280-293 (2004).
18. Sherman ME, Solomon D, Schiffman M; ASCUS LSIL Triage Study Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am. J. Clin. Pathol. 116, 386-394 (2001).
19. Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52, 342-362 (2002).
20. Wright TC, Cox JT, Massad LS, Carlson J, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am. J. Obstet. Gynecol. 189, 295-304 (2003).
21. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 287, 2120-2129 (2002).
22. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92(9), 690-698 (2000). •• Excellent review on human papillomavirus and pathogenesis of cervical neoplasia.
23. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2(5), 342-350 (2002).
24. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79, 328-337 (1992).
25. Munger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirusinduced oncogenesis. J. Virol. 78(21), 11451-1160 (2004).
26. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68(2), 362-372 (2004). •• Authoritative review on human papillomavirus biology.
27. Clarke B, Chetty R. Cell cycle alterations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 82(2), 238-246 (2001). •• Key review on human papillomavirusinduced alterations of the cell cycle in cervical neoplasia.
28. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The human papillomavirus E7 oncoprotein inhibits transforming growth factor-β signaling by blocking binding of the Smad complex to its target sequence. J. Biol. Chem. 277(41), 38557-38564 (2002).
29. McDougall JK. Immortalization and transformation of human cells by human papillomavirus. Curr. Top. Microbiol. Immunol. 186, 101-119 (1994).
30. Demers GW, Halbert CL, Galloway DA. Elevated wild-type p53 protein levels in human epithelial cells immortalized by the human papillomavirus type 16 E7 gene. Virology 198(1), 169-174 (1994).
31. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc. Natl Acad. Sci. USA 95(5), 2290-2295 (1998).
32. Duensing S, Munger K. Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins. Prog. Cell Cycle Res. 5, 383-391 (2003).
33. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 109(2), 157-162 (2004).
34. Erlandsson F, Wahlby C, Ekholm-Reed S, Hellstrom AC, Bengtsson E, Zetterberg A. Abnormal expression pattern of cyclin E in tumor cells. Int. J. Cancer 104(3), 369-375 (2003).
35. Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R. Cyclins and proliferation markers in early squamous cell cervical carcinoma. Gynecol. Oncol. 92(1), 40-46 (2004).
36. El-Ghobashy AA, Shaaba AM, Herod J, Innes J, Prime W, Herrington CS. Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix. Gynecol. Oncol. 92(2), 628-634 (2004).
37. INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92(2), 276-284 (2001).
38. Tringler B, Gup CJ, Singh M et al. Evaluation of p16INK4A and pRb expression in cervical squamous and glandular neoplasia. Hum. Pathol. 35(6), 689-696 (2004).
39. Schorge JO, Lea JS, Elias KJ et al. p16INK4A as a molecular biomarker of cervical adenocarcinoma. Am. J. Obstet. Gynecol. 190(3), 668-673 (2004).
40. Baege AC, Berger A, Schlegel R, Veldman T, Schlegel R. Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity. Am. J. Pathol. 160(4), 1251-1257 (2002).
41. McMurray HR, McCance DJ. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-myc and release of USF-mediated repression. J. Virol. 77(18), 9852-9861 (2003).
42. Veldman T, Liu X, Yuan H, Schlegel R. Human papillomavirus E6 and myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl Acad. Sci. USA 100(14), 8211-8216 (2003).
43. INK4A are complimentary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am. J. Surg. Pathol. 25, 884-891 (2001).
44. Dunton CJ, van Hoeven KH, Kovatich AJ et al. Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia. Gynecol. Oncol. 64, 451-455 (1997).
45. Sahebali S, Depuydt CE, Segers K, Vereecken AJ, Van Marck E, Boger JJ. Ki-67 immunocytochemistry in liquid based cervical cytology: use as an adjunctive tool? J. Clin. Pathol. 56, 681-686 (2003).
46. Boon ME, Kleinschmidt-Guy ED, Wijsman-Grootendorst A, Hoogeveen MM. Upgrading unsatisfactory cervical smears with the MIB-1 method. Diagn. Cytopathol. 15, 270-276 (1996).
47. Boon ME, Vinkestein A, van Binsbergen-Ingelse A, van Haaften C. Significance of MIB-1 staining in smears with atypical glandular cells. Diagn. Cytoapthol. 31, 77-82 (2004).
48. Goel MM, Mehrotra A, Singh U, Gupta HP, Misra JS. MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical Pap smear. Diagn. Cytopathol. 33, 15-19 (2005).
49. INK4A as an adjunct marker in liquid-based cervical cytology. Int. J. Cancer. 108(6), 871-876 (2004).
50. INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int. J. Gynecol. Pathol. 22(4), 378-385 (2003).
51. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur. J. Cancer 38(17), 2229-2242 (2002).
52. INK4A antigen in thin-layer specimens. Acta Cytol. 46(1), 25-29 (2002).
53. INK4A in liquid-based specimens (SurePath™) as marker of cervical dysplasia and neoplasia. Diagn. Cytopathol. 27(6), 365-370 (2002).
54. INK4A and hybrid capture II human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 122(6), 894-901 (2004).
55. INK4A in Pap smears containing ASCUS from the uterine cervix. Gynecol. Oncol. 91(1), 201-208 (2003).
56. INK4A, CDC6 and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J. Clin. Pathol. 58(5), 525-534 (2005).
57. Chang Y, Laimins LA. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus 31. J. Virol. 74(9), 4174-4182 (2000).
58. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus Type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J. Virol. 75(9), 4283-4296 (2001).
59. Thomas JT, Oh ST, Terhune SS et al. Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J. Virol. 75(16), 7564-7571 (2001).
60. Alazawi W, Pett M, Arch B et al. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res. 62(23), 6959-6965 (2002).
61. Ruutu M, Peitsaro P, Johansson B et al. Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral infection. Int. J. Cancer 100(3), 318-322 (2002).
62. Berger AJ, Baege A, Guillemette T et al. Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am. J. Pathol. 161(2), 603-610 (2002).
63. Chen Y, Miller C, Mosher R et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 63(8), 1927-1935 (2003). •• Excellent example of biomarker discovery in cervical carcinoma.
64. Rosty C, Sheffer M, Tsafrir D et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24(47), 7094-7104 (2005). •• Another excellent example of biomarker discovery in cervical neoplasia and description of proliferation signatures in cervical neoplasia.
65. Kanda K, Ueda M, Futakuchi H et al. Transcriptional expression of the genes implicated in angiogenesis and tumor invasion in cervical carcinomas. Gynecol. Oncol. 98(3), 453-461 (2005).
66. Ranamukhaarachchi DG, Unger ER, Vernon SD, Lee D, Rajeevan MS. Gene expression profiling of dysplastic differentiation in cervical epithelial cells harboring human papillomavirus 16. Genomics 85(6), 727-738 (2005).
67. Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E, Manavi M. cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. Cancer Genet. Cytogenet. 158(1), 35-42 (2005).
68. Santin AD, Zhan F, Bignotti E et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 331(2), 269-291 (2005).
69. Garner-Hamrick PA, Fostel JM, Chien WM et al. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J. Virol. 78(17), 9041-9050 (2004). •• Excellent example of microarray expression analysis and biomarker identification in an oncogenic human papillomavirus raft keratinocyte cell-line model system.
70. Genther Williams SM, Disbrow GL, Schlegel R, Lee D, Threadgill DW, Lambert PF. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65(15), 6534-6542 (2005).
71. Akerman GS, Tolleson WH, Brown KL et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 61(9), 3837-3843 (2001).
72. Crusius K, Rodriquez I, Alonso A. The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. Virus Genes 20(1), 65-69 (2000).
73. Chakrabarti O, Veeraraghavalu K, Tergaonkar V et al. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J. Virol. 78(11), 5934-5945 (2004).
74. Branca M, Ciotti M, Santini D et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am. J. Clin. Pathol. 122(6), 902-911 (2004).
75. Uren A, Fallen S, Yuan H et al. Activation of canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 65(14), 6199-6206 (2005).
76. Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int. J. Gynecol. Cancer 13(5), 640-646 (2003).
77. Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG. Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum. Pathol. 34(3), 240-245 (2003).
78. Rodriques-Sastre MA, Gonzalez-Maya L, Delgado R et al. Abnormal distribution of E-cadherin and β-catenin in different histologic types of cancer of the uterine cervix. Gynecol. Oncol. 97(2), 330-336 (2005).
79. Fadare O, Reddy H, Wang J, Hileeto D, Schwartz PE, Zheng W. E-cadherin and β-catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World J. Surg. Oncol. 3(1), 38 (2005).
80. Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R. E-cadherin and catenins in early squamous cervical carcinoma. Gynecol. Oncol. 94(2), 521-527 (2004).
81. Imura J, Ichikawa K, Takeda J, Fujimori T. β-catenin expression as a prognostic indicator in cervical adenocarcinoma. Int. J. Mol. Med. 8(4), 353-358 (2001).
82. Diffler JFX, Labib K. The chromosome replication cycle. J. Cell Sci. 115(5), 869-872 (2002).
83. Murphy N, Ring M, Heffron CC et al. Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Mod. Pathol. 18(6) 844-849 (2005).
84. Bonds L, Baker P, Gup C, Shroyer KR. Immunohistochemical localization of cdc6 in squamous and glandular neoplasia of the uterine cervix. Arch. Pathol. Lab. Med. 126(10), 1164-1168 (2002).
85. Williams GH, Romanowski P, Morris L et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc. Natl Acad. Sci. USA 95(25), 14932-14937 (1998). •• First reported application of minichromosome maintenance protein detection in cervical Papanicolaou smears.
86. Freeman A, Morris LS, Mills AD et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin. Cancer Res. 5(8), 2121-2132 (1999). •• Key article on the detection of minichromosome maintenance proteins in a variety of human cancers.
87. Brake T, Connor JP, Petereit DG, Lambert PF. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance 7 protein as an informative biomarker of human cervical cancer. Cancer Res. 63(23), 8173-8180 (2003).
88. Malinowski DP, Parker MR, Sampson SJ et al. Development of a molecular diagnostic assay to detect moderate-severe dysplasia and cervical neoplasia. Acta Cytol. 48(5), 696 (2004).
89. Sampson SJ, Parker MR, Hessling JJ et al. Data comparison of three molecular markers (MCM7, p16 and integrin β6) for the detection of cervical dysplasia in SurePath™ cytology specimens. Acta Cytol. 48(5), 658 (2004).
90. Branca M, Giorgi C, Ciotti M et al. Over-expression of topoisomerase IIα is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognsis in cervical cancer of HPV clearnace after cone treatment. Int. J. Gynecol. Pathol. 25, 383-392 (2006).
91. Sobel G, Szabo I, Paska C et al. Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. Pathol. Oncol. Res. 11(1), 26-31 (2005).
92. Lee JW, Lee SJ, Seo J et al. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol. Oncol. 97(1), 53-59 (2005).
93. Sobel G, Paska C, Szabo I, Kiss A, Kadar A, Schaff Z. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum. Pathol. 36(2), 162-169 (2005).
94. Vazquez-Ortiz G, Pina-Sanchez P, Vasquez K et al. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 5, 68 (2005).
95. Skyldberg B, Salo S, Eriksson E et al. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl Cancer Inst. 91(21), 1882-1887 (1999).
96. Stoltzfus P, Salo S, Eriksson E et al. Laminin-5γ2 chain expression facilitates detection of invasive squamous cell carcinoma of the uterine cervix. Int. J. Gynecol. Pathol. 23(3), 215-222 (2004).
97. Gruber G, Hess J, Stiefel C et al. Correlation between the tumoral expression of β3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br. J. Cancer 92(1), 41-46 (2005).
98. 3 integrin receptors in non-malignant and malignant human cervical tumor tissues. J. Exp. Clin. Cancer Res. 20(2), 269-275 (2001).
99. 3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J. Cancer Res. Clin. Oncol. 127(11), 653-658 (2001).
100. Pirog EC, Baergen RN, Soslow RA et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostaining. Am. J. Sur. Pathol. 26(1), 70-75 (2002).
101. INK4A expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod. Pathol. 16(7), 665-673 (2003).
102. INK4A expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol. Oncol. 97(1), 35-40 (2005).
103. Qiao X, Bhuiya TA, Spitzer M. Differentiating high-grade cervical intracepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E and p16 immunohistochemical assays. J. Low. Genit. Tract Dis. 9, 100-107 (2005).
104. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB-1, Bcl2, and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasiam endometriosis and microglandular hyperplasia. Histopathology 41, 313-321 (2002).
105. Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-α in cervical squamous intraepithelial lesions. Hum. Pathol. 35(11), 1376-1384 (2004).
106. Baak JP, Kruse AJ, Garland SM et al. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Am. J. Surg. Pathol. 29(8), 1062-1066 (2005).
107. Kruse AJ, Baak JP, de Bruin PC et al. The HS Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J. Pathol. 193, 48-54 (2001).
108. Popiolek D, Ventura K, Mittal K. Distinction of low-grade squamous intraepithelial lesions from high-grade squamous intraepithelial lesions based on quantitative analysis of proliferation activity. Oncol. Rep. 11, 687-691 (2004).
109. Kruse AJ, Baak J, Janssen EA et al. Ki67 predcits progression in early CIN: validation of a multivariate progression-risk model. Cell. Oncol. 26, 13-20 (2004).
110. Kruse AJ, Baak JP, Janssen EA et al. Low- and high-risk CIN1 and 2 lesions: prospective predictive value of grade HPV and Ki-67 immuno-quantitative variables. J. Pathol. 199, 462-470 (2003).
111. Kruse AJ, Gudlaugsson E, Helliesen T et al. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk. Anal. Quant. Cytol. Histol. 26, 134-140 (2004).
112. Kruse AJ, Skaland I, Janssen EA et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int. J. Gynecol. Pathol. 23, 100-109 (2004).
113. Baak JP, Kruse AJ, Janssen E, van Diermen B. Predictive testing of early CIN behavior by molecular biomarkers. Cell. Oncol. 27, 277-280 (2005).
114. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-α and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 108(5), 324-30 (2006).
115. Kelly D, Kincaid E, Fansler Z, Rosenthal DL, Clark DP. Detection of cervical high-grade squamous intraepithelial lesions from cytologicsamples using a novel immunocytochemical assay (ProEx C). Cancer 108(6), 494-500 (2006).